Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial

详细信息    查看全文

• 作者：Roman Rouzier^a ; ^{roman.rouzier@curie.fr} ; Sé ; bastien Gouy^b ; Fré ; dé ; ric Selle^c ; Eric Lambaudie^d ; Anne Floquet^e ; Virginie Fourchotte^a ; Christophe Pomel^f ; Pierre-Emmanuel Colombo^g ; Elsa Kalbacher^h ; Sandrine Martin-Francoiseⁱ ; Raffaele Fauvet^j ; Philippe Follana^k ; Anne Lesoin^l ; Fabrice Lecuru^m ; Youssef Ghaziⁿ ; Julien Dupin^o ; Elisabeth Chereau^d ; Sarah Zohar^p ; Paul Cottu^a ; Florence Jolyⁱ ; ^{f.joly@baclesse.unicancer.fr}
• 关键词：Bevacizumab ; Interval debulking surgery ; Neoadjuvant chemotherapy
• 刊名：European Journal of Cancer
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：70
• 期：Complete
• 页码：133-142
• 全文大小：1177 K
• 卷排序：70

文摘

We present findings from the ANTHALYA study in women with advanced ovarian cancer. The complete resection rate at interval debulking surgery was examined. Bevacizumab-containing neoadjuvant therapy achieved 58.6% complete resection rate at interval debulking surgery. The incidence of perioperative complications with bevacizumab was acceptable. The role of bevacizumab in this setting should be further investigated.